CA2988330A1 - 4,6-pyrimidinylene derivatives and uses thereof - Google Patents

4,6-pyrimidinylene derivatives and uses thereof Download PDF

Info

Publication number
CA2988330A1
CA2988330A1 CA2988330A CA2988330A CA2988330A1 CA 2988330 A1 CA2988330 A1 CA 2988330A1 CA 2988330 A CA2988330 A CA 2988330A CA 2988330 A CA2988330 A CA 2988330A CA 2988330 A1 CA2988330 A1 CA 2988330A1
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
compound
certain embodiments
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2988330A
Other languages
English (en)
French (fr)
Inventor
Nathanael S Gray
Tinghu Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA2988330A1 publication Critical patent/CA2988330A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2988330A 2015-06-26 2016-06-24 4,6-pyrimidinylene derivatives and uses thereof Pending CA2988330A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562185334P 2015-06-26 2015-06-26
US62/185,334 2015-06-26
PCT/US2016/039312 WO2016210296A1 (en) 2015-06-26 2016-06-24 4,6-pyrimidinylene derivatives and uses thereof

Publications (1)

Publication Number Publication Date
CA2988330A1 true CA2988330A1 (en) 2016-12-29

Family

ID=57585796

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2988330A Pending CA2988330A1 (en) 2015-06-26 2016-06-24 4,6-pyrimidinylene derivatives and uses thereof

Country Status (6)

Country Link
US (2) US10695346B2 (enExample)
EP (1) EP3313530B1 (enExample)
JP (1) JP6947651B2 (enExample)
AU (1) AU2016283105C1 (enExample)
CA (1) CA2988330A1 (enExample)
WO (1) WO2016210296A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2972239A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
WO2017073065A1 (ja) * 2015-10-28 2017-05-04 公益財団法人静岡県産業振興財団 新規抗がん薬
US11542233B2 (en) * 2016-12-23 2023-01-03 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use
JP7569688B2 (ja) * 2017-12-22 2024-10-18 ハイバーセル，インコーポレイテッド ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体
WO2019126733A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
CN111936484A (zh) * 2017-12-22 2020-11-13 拉文纳制药公司 作为磷脂酰肌醇磷酸激酶抑制剂的色烯并吡啶衍生物
PT3784664T (pt) 2018-04-26 2025-04-23 Pfizer Derivados da 2-amino-piridina ou da 2-amino-pirimidina como inibidores da quinase dependente da ciclina
WO2019213403A1 (en) 2018-05-02 2019-11-07 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
JP2021529740A (ja) 2018-06-29 2021-11-04 キネート バイオファーマ インク． サイクリン依存性キナーゼの阻害剤
EP3833353A4 (en) * 2018-08-10 2022-08-24 Yale University Small-molecule pi5p4k alpha/beta inhibitors and methods of treatment using same
EP3902542A4 (en) 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
TW202112767A (zh) * 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
TW202112784A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物
CN113698391B (zh) * 2020-05-21 2023-06-06 上海拓界生物医药科技有限公司 4-氨基嘧啶或2-氨基三嗪类化合物及其制备方法
JP2023554673A (ja) * 2020-12-21 2023-12-28 ヤンセン ファーマシューティカ エヌ．ベー． サイクリン依存性キナーゼ７（ｃｄｋ７）阻害剤としての三環式ピリミジン
CA3173819A1 (en) * 2020-12-23 2022-06-30 Dana-Farber Cancer Institute, Inc. Small molecule degraders of phosphatidylinositol-5-phosphate 4-kinase type 2 and uses thereof
WO2022246025A1 (en) * 2021-05-20 2022-11-24 Dana-Farber Cancer Institute, Inc. Inhibitors and degraders of pip4k protein
MX2024002139A (es) 2021-08-18 2024-03-06 Chemocentryx Inc Arilsulfonil(hidroxi)piperidinas como inhibidores de ccr6.
WO2023023534A2 (en) 2021-08-18 2023-02-23 Chemocentryx, Inc. Aryl sulfonyl compounds as ccr6 inhibitors
CN113698357A (zh) * 2021-09-29 2021-11-26 守恒(厦门)医疗科技有限公司 磺胺嘧啶类衍生物及其在抗肿瘤药物的应用
CN113861130A (zh) * 2021-09-29 2021-12-31 守恒(厦门)医疗科技有限公司 联苯磺胺噻二唑类衍生物及其在抗肿瘤药物的应用
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
WO2023227125A1 (zh) * 2022-05-26 2023-11-30 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
CN116903587B (zh) * 2023-06-01 2024-03-22 三峡大学 一种角鲨烯环氧酶抑制剂及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1205276A (en) * 1915-03-29 1916-11-21 Robert C Sharpe Machine or instrument for cracking nuts.
KR100848067B1 (ko) * 2003-12-25 2008-07-23 니뽄 신야쿠 가부시키가이샤 아미드 유도체 및 의약
WO2007076474A1 (en) * 2005-12-23 2007-07-05 Kalypsys, Inc. Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
WO2008079460A2 (en) 2006-09-05 2008-07-03 Emory University Tyrosine kinase inhibitors for prevention or treatment of infection
AU2009271019A1 (en) * 2008-07-14 2010-01-21 Gilead Sciences, Inc. Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
US20120165309A1 (en) * 2009-02-12 2012-06-28 Astellas Pharma Inc. Hetero ring derivative
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
CN102408408A (zh) * 2010-09-20 2012-04-11 北大方正集团有限公司 具有抗肿瘤作用的芳基脲衍生物
CN102406646B (zh) * 2010-09-20 2015-09-09 北大方正集团有限公司 芳基脲衍生物用于制备治疗移植排斥药物的用途
CN102406644A (zh) 2010-09-20 2012-04-11 北大方正集团有限公司 芳基脲衍生物用于制备治疗移植排斥药物的新用途
JP6106685B2 (ja) * 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
US9879003B2 (en) 2012-04-11 2018-01-30 Dana-Farber Cancer Institute, Inc. Host targeted inhibitors of dengue virus and other viruses
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN103242341B (zh) 2013-04-19 2015-12-09 中国科学院广州生物医药与健康研究院 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用
CN104177363B (zh) 2013-05-24 2018-06-05 江苏先声药业有限公司 双环杂环胺类Hedgehog信号通路抑制剂
EP3057955B1 (en) * 2013-10-18 2018-04-11 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
EP3057956B1 (en) * 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
AU2014361798B2 (en) * 2013-12-13 2020-06-11 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2016201370A1 (en) * 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP3313529A4 (en) 2015-06-26 2018-12-26 Dana Farber Cancer Institute, Inc. Fused bicyclic pyrimidine derivatives and uses thereof

Also Published As

Publication number Publication date
US20210315894A9 (en) 2021-10-14
US20180344733A9 (en) 2018-12-06
EP3313530A4 (en) 2019-02-20
EP3313530B1 (en) 2022-10-05
AU2016283105B2 (en) 2020-09-24
AU2016283105A1 (en) 2017-12-21
AU2016283105C1 (en) 2023-02-02
US20180110778A1 (en) 2018-04-26
WO2016210296A1 (en) 2016-12-29
JP2018522866A (ja) 2018-08-16
US20200338075A1 (en) 2020-10-29
JP6947651B2 (ja) 2021-10-13
US10695346B2 (en) 2020-06-30
HK1254654A1 (en) 2019-07-26
EP3313530A1 (en) 2018-05-02

Similar Documents

Publication Publication Date Title
JP7200282B2 (ja) サイクリン依存性キナーゼの阻害剤
AU2016283105B2 (en) 4,6-pyrimidinylene derivatives and uses thereof
US10342798B2 (en) Fused bicyclic pyrimidine derivatives and uses thereof
AU2015371251B2 (en) Inhibitors of cyclin-dependent kinase 7 (CDK7)
AU2019413694B2 (en) Inhibitors of cyclin-dependent kinase 7 and uses thereof
CA2996978A1 (en) Inhibitors of cyclin-dependent kinases
AU2020357983B2 (en) Tricyclic kinase inhibitors and uses thereof
HK1254654B (en) 4,6-pyrimidinylene derivatives and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210517

EEER Examination request

Effective date: 20210517

EEER Examination request

Effective date: 20210517

EEER Examination request

Effective date: 20210517

EEER Examination request

Effective date: 20210517

EEER Examination request

Effective date: 20210517

EEER Examination request

Effective date: 20210517

EEER Examination request

Effective date: 20210517

EEER Examination request

Effective date: 20210517

EEER Examination request

Effective date: 20210517